Exploring the potential of butyrate as a therapeutic agent for non-communicable diseases: Translational research from lab to patient

Keyphrases

• Therapeutic Agents 100%
• Non-communicable Diseases 100%
• Translational Research 100%
• Butyrate 100%
• Pharmacodynamics 22%
• T Helper Cells 16%
• Pharmacokinetics 16%
• Intestinal Epithelial Cells 16%
• Lipopolysaccharide 11%
• Chronic Disease 11%
• Peripheral Blood Mononuclear Cells 11%
• Intestine 11%
• Randomized Placebo-controlled Trial 11%
• Interferon-γ 11%
• CXCL10 11%
• Histone Deacetylase Inhibitor (HDACi) 11%
• Gut Microbiome 11%
• Sustained-release Tablets 11%
• Hand Osteoarthritis 11%
• Protective Effect 5%
• Therapeutic Potential 5%
• Allergic Diseases 5%
• Tumor Necrosis Factor-α 5%
• Inflammation 5%
• Disease-based 5%
• Immune Cells 5%
• Protective Behavior 5%
• Mechanism of Action 5%
• Cell-to-cell 5%
• Treg 5%
• Lamina Propria 5%
• Diabetes 5%
• T Helper 17 (Th17) 5%
• Regulatory T (Treg) Cells 5%
• Caco-2 Cells 5%
• Anti-inflammatory Effect 5%
• Cardiovascular Disease 5%
• Laboratory Setting 5%
• Co-culture Model 5%
• HT-29 5%
• CD28 5%
• Non-canonical 5%
• Low-grade Inflammation 5%
• Barrier Function 5%
• Caco-2 5%
• In Vitro Experiment 5%
• Immune Disorders 5%
• Cell Phenotype 5%
• Cytokine Release 5%
• Sustained Release 5%
• Cell Activation 5%
• Gut Barrier Function 5%
• Active Ingredients 5%
• Gut Homeostasis 5%
• Enhanced Permeability 5%
• Dysbiosis 5%
• Systemic Inflammation Response Index 5%
• Trichostatin A 5%
• Gut Integrity 5%
• Intestinal Barrier Dysfunction 5%
• Systemic Lipopolysaccharide 5%
• STAT1 Pathway 5%
• Chronic Respiratory Diseases 5%
• Permeability to Macromolecules 5%

Immunology and Microbiology

• Infectious Disease 100%
• Pharmacodynamics 57%
• T Helper Cell 42%
• Sustained Drug Release 42%
• Pharmacokinetics 42%
• Peripheral Blood Mononuclear Cell 28%
• Regulatory T Cell 28%
• Gut Microbiome 28%
• Intestine 28%
• CXCL10 28%
• Cytokine 28%
• Osteoarthritis 28%
• Interferon Gamma 28%
• Immune Disorder 14%
• Systemic Inflammation 14%
• CD3 Antigen 14%
• CD28 14%
• Immunocompetent Cell 14%
• Homeostasis 14%
• Tumor Necrosis Factor Alpha 14%
• Cell Activation 14%
• Coculture 14%
• Antiinflammatory Activity 14%
• Cytokine Release 14%
• Macromolecule 14%
• Lamina Propria 14%
• STAT1 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Butyrate 100%
• Non Communicable Disease 100%
• Tablet 27%
• Pharmacodynamics 22%
• Sustained Release 16%
• Lipopolysaccharide 16%
• Pharmacokinetics 16%
• Cytokine 16%
• Inflammation 16%
• Disease 16%
• Controlled Clinical Trial 11%
• Placebo 11%
• Chronic Disease 11%
• Gamma Interferon 11%
• Hand Osteoarthritis 11%
• Microbiome 11%
• Clinical Study 5%
• Anti-Inflammatory Drug 5%
• Antiinflammatory Activity 5%
• Tumor Necrosis Factor 5%
• Chronic Respiratory Tract Disease 5%
• Histone Deacetylase Inhibitor 5%
• Trichostatin A 5%
• Dysbiosis 5%
• Histone Deacetylase 5%